$MRK - $UNVC CBD JV speculation running rampant on
Post# of 87029
(Total Views: 1196)
Posted On: 10/27/2018 11:26:53 PM
$MRK - $UNVC CBD JV speculation running rampant online. MilliporeSigma patch will be the delivery mechanism. Fits into this newspaper article (credit to Kgem):
.....Additionally, Merck may be entertaining a spinoff that would give it a prominent foothold in the cannabis processing market.
Your editor Sean McCloskey divulged this info to me, after sitting down to lunch with the Segment Marketing Manager of MillaporeSigma (a division of Merck), at of all places, a marijuana investors conference in Toronto this past August.
Whether we see a pot spinoff from Merck one day is anyone’s guess, but based on the dots we can connect, there’s a betting man’s chance we do.
Since we first suggested Merck in May shares are up over 18%. This even after the market’s broad selloff the past two weeks. Clearly there are strong tailwinds at work.
If their drug Keytruda successfully navigates the final stages of the FDA gauntlet, the gains from this revenue stream should help boost shares.
And if my suspicions are correct that a Merck is planning a cannabis spinoff venture, their shares could really run higher.
Ray Blanco (TechProfitsDaily@p.sevenfigurepublishing.com)
Speculation on Merck board running wild since last week. It's going public:
https://speculatingstocks.com/pulse/stock/MRK/
.....Additionally, Merck may be entertaining a spinoff that would give it a prominent foothold in the cannabis processing market.
Your editor Sean McCloskey divulged this info to me, after sitting down to lunch with the Segment Marketing Manager of MillaporeSigma (a division of Merck), at of all places, a marijuana investors conference in Toronto this past August.
Whether we see a pot spinoff from Merck one day is anyone’s guess, but based on the dots we can connect, there’s a betting man’s chance we do.
Since we first suggested Merck in May shares are up over 18%. This even after the market’s broad selloff the past two weeks. Clearly there are strong tailwinds at work.
If their drug Keytruda successfully navigates the final stages of the FDA gauntlet, the gains from this revenue stream should help boost shares.
And if my suspicions are correct that a Merck is planning a cannabis spinoff venture, their shares could really run higher.
Ray Blanco (TechProfitsDaily@p.sevenfigurepublishing.com)
Speculation on Merck board running wild since last week. It's going public:
https://speculatingstocks.com/pulse/stock/MRK/
(1)
(0)